^(131)碘治疗Graves病的临床价值

Clinical value of ^(131)I therapy in the treatment of Graves' disease

目的探讨放射性131碘(131I)治疗弥漫性毒性甲肿(Graves病)的临床应用价值。方法对93例Graves病进行首次131I治疗后观察其效果,并与抗甲亢药物(85例)和手术治疗(82例)的效益比对,进行相关分析。结果首次131I治疗Graves病总治愈率为68.8%。总好转率为11.8%,总有效率为80.6%;Graves病131I治疗与抗甲亢药物治疗治愈率差异有统计学意义(P<0.05),治疗周期明显缩短;与手术治疗治愈率比较差异无统计学意义(P>0.05),但治疗费用大幅下降。结论放射性131碘治疗毒性弥漫性甲肿具有稳定有效、周期短、价格低、安全性高等特点,在治疗甲亢的领域值得推广。

Objective To investigate the clinical value of 13~I therapy in the treatment of Graves＇ disease （diffuse toxic goiter. Methods Ninety-three patients with Graves＇ disease were treated by 131I therapy, then the clinical effects were observed and compared with that of antithyroid drugs （85 cases） operation （82 cases）. Results The total cure rate, the total improvement rate, the total effective rate after the first 131I therapy were 68.8%, 11.8%, 80.6%, respectively. Compared with antithyroid drugs, 131I therapy had significantly higher cure rate and shorter treatment cycle, （P〈0.05）.131I therapy showed no statistically significant difference with operation in cure rate （P〉0.05）, but the treatment costs plunged. Conclusion The treatment of Graves＇ disease with 131I is stable and effective, with short cycle, low price and high security features, which is worth popularizing.